Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Scania Super Green Truck 2024

Each year, all the manufacturers of heavy trucks in Europe are invited to the Green Truck comparison test. It is organised by two German trade magazines to identify the most transport-efficient long-haul truck. Apart from a brief hiccup in 2023 – when Scania came second – the Södertälje-based manufacturer has won and been named “Green Truck” for seven out of the last eight tests. In fact, Scania has won the test nine out of the 14 times that it has been held since the competition began in 2011 – an impressive feat!“Scania participates in many press tests in Europe, but the Green Truck Award

BiBB receives patent approval for EndoDrill in India

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces today that the Indian Patent Office has granted the first patent for EndoDrill[®]. The patent provides broad protection of the EndoDrill[®] system until October 2039.The approved Indian patent 532933 originates from the patent application IN202127017788 from patent family 1 and protects the EndoDrill[®] product series, the world's first market-cleared electric-driven biopsy instrument for endoscopy. BiBB has

Freetrailer expands to the Netherlands

Freetrailer Group A/S is partnering with Christian Tepper, who has a strong digital mindset, and long-lasting experience from within the industry. Christian will front our ambitions in the Netherlands as Sales Manager.The Netherlands has been on the roadmap for a while due to the market maturity within rental of trailers. Freetrailer is ready to escalate operationally, and the area in and around Amsterdam has been selected as our focus when we will be ready with our concept for our partners and end-users in Q1 2025.   For 9 years Christian Tepper was the owner of the second largest

Gradientech strengthens its commercial management team

The diagnostics company Gradientech today announces that AnnaLotta Schiller Vestergren has been appointed as the company’s Chief Commercial Officer and part of the management team. AnnaLotta has extensive experience with international commercial organisations, with nearly 30 years of leading positions in life science and diagnostics.“I´m very pleased to welcome AnnaLotta to join the Gradientech team. With a background in molecular biology and bacteriology and extensive experience in international sales and business development from major life science companies as well as smaller emerging

Spinomenal Debuts Queen of the Amazon Slot

Leading iGaming content provider Spinomenal has released its new hit, Queen of the Amazon. Set amongst the lush rainforest, this 5x4 slot welcomes players on an adventure where treasure awaits intrepid explorers.A majestic Amazon headdress, tiger, gorilla, and snake, make up the Medium symbols on the reels. At the heart of the story stands the queen herself, representing the Wild symbol. Her symbol can substitute for any other symbol on the reels, except for the Free Spins and Bonus symbols. Discovering five Wilds on a winning line will multiply the bet line by 2000.  Synced Reels, where

Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with a TP53 mutation presented in an oral presentation at the 50th EBMT annual meeting

Stockholm, April 18, 2024 – Immedica’s partner Actinium Pharmaceuticals, Inc. presented results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation in an oral presentation at the 50th Annual meeting of the European Society for Blood and Marrow Trasnplantation (EBMT) held April 14 – 17, 2024, in Glasgow, Scotland. Iomab-B is a targeted radiotherapy agent comprised of an anti-CD45 monoclonal antibody conjugated to Iodine-131 radioisotope payload. The Phase 3 SIERRA trial enrolled 153 patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and

Polygiene Group invites you to a presentation of the first quarter 2024

Polygiene Group will publish its quarterly report for the first quarter (January-March) on April 25, 2024, at 8.00 CET. In connection to the announcement, Polygiene Group invites you to a video conference on the same day at 10.00 CET.· Presentation of the quarterly report, CEO Ulrika Björk · Review of the financial results, CFO Niklas Blomstedt The conference is expected to last 45 minutes and will be held in English.         Registration is made via the link below no later than April 24, 2024. Instructions regarding access to the conference will be sent out via e-mail when you

Invitation to Hoist Finance first quarter 2024 presentation

Hoist Finance will publish its Q1 2024 report on 3 May 2024, at approximately 07:30 AM (CEST). A combined presentation and teleconference will be held at 09:30 AM (CEST). Harry Vranjes, CEO, and Christian Wallentin, CFO, will present and comment on the report. If you wish to participate via webcast, please use the link below. You can ask written questions via the webcast. https://ir.financialhearings.com/hoist-finance-q1-report-2024   If you wish to participate via teleconference please register on the link below. After registration you will be provided with phone numbers and a

SEB’s The Green Bond report: Fast, furious, and fair transition?

The latest issue of SEB’s The Green Bond report is dedicated to the question of how to scale energy transition investments at the speed required to reach net-zero emissions and in a manner that is socially inclusive. Amid rising populism and an escalating geopolitical race for clean technology competitiveness and energy security, green industrial policies may lead faltering energy transition investments and stagnating sustainable debt markets back to growth.  “The clean energy transition is showing no signs of a break with the past year’s stagnating trend,” says Thomas Thygesen, Head of

Pihlajalinna Plc publishes Interim Report for January 1–March 31, 2024 on Friday, 3 May, 2024

Pihlajalinna Plc                     Investor News                       18 April 2024 at 11:00 a.m.Pihlajalinna Plc publishes Interim Report for January 1–March 31, 2024 on Friday, 3 May, 2024 Pihlajalinna Plc will publish the Interim Report for the period of January 1–March 31, 2024 on Friday, 3 May, 2024 at approximately 8.00 a.m. The release will be available on the company website . Live webcast for analysts and mediaPihlajalinna will organize a live webcast meeting for analysts and media, on Friday,

Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group

Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, has secured continued production of Alpha1-peptide with the Swiss public company Polypeptide Group. The new production, at a larger scale, will be essential for the clinical trial program in bladder cancer, currently advancing towards Phase III.Hamlet BioPharma announces an important milestone by advancing pharmaceutical manufacturing of the Alpha1 peptide with the Polypeptide Group, a leading CDMO company in peptide synthesis. Through a cooperative effort with the

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 90 – 18 APRIL 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 30/24 and 31/24.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Communications & Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Tranter contributes to fossil fuels reduction in steel production.

Vanersborg, Sweden. Tranter has secured an order for a cutting-edge direct reduced iron (DRI), green steel plant set to be constructed in Germany. The DRI plant reduces its carbon footprint significantly by using green hydrogen and carbon capture, helping to achieve NetZero goals by 2030.Tranter’s plate and frame heat exchangers will be used in the process to capture and separate the carbon dioxide coming from the energy intense steel production process. The order is for four large plate and frame heat exchangers in stainless steel with extra hard EPDM gaskets that will be used for heat

From today, the new STENOCARE THC/CBD medical cannabis oil product is available for sale in Denmark

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO On February 26, 2024, STENOCARE A/S (“Stenocare”) announced, that it had received approval to supply a new THC/CBD medical cannabis oil product under the Danish Pilot Programme. Starting today the new product is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot. Out of the many suppliers seeking approval to sell their products, Stenocare has been in a clear leadership position from the start of the Pilot in 2018 and is the only supplier of three different

SemiQon’s quantum processor testing and measurement facilities at the VTT MIKES premises up and running

SemiQon is the first company to operate within the laboratory premises of the Finnish National Metrology Institute VTT MIKES. The new facilities support SemiQon’s commitment to advancing world-class measurement expertise and infrastructure for building scalable quantum hardware.ESPOO, Finland (April 18th, 2024) SemiQon's measurement and testing facilities within the premises of the National Metrology Institute VTT MIKES are now finalized and fully operational. SemiQon will be the first deep-tech company benefiting from one of the best metrological research infrastructures in the world for

Genexis joins 25GS-PON MSA Group

Genexis is now one of the 64 current members and industry leaders to have joined the initiative.25GS-PON Multi-Source Agreement (MSA) Group aims to promote and accelerate the development of 25 Gigabit Symmetric Passive Optical Network (25GS-PON) technology and define its specifications. Many of the world’s top operators and vendors see 25GS-PON as a crucial technology. It provides a cost-effective and timely network upgrade path that can meet the needs of the mobile 5G era and large-scale enterprises, where symmetrical connections become increasingly important. “We are delighted to join

NAVA – a gamechanger for neonatal care in Slovakia

When using Getinge’s patented Neurally Adjusted Ventilatory Assist (NAVA) with diaphragm monitoring (Edi) for the first time in 2021, it soon became clear to the neonatal team in the F.D. Roosevelt University Hospital in Banska Bystrica, Slovakia, that the solution would become a gamechanger for their treatment of premature babies. The first case for the F.D. Roosevelt University Hospital in Banska Bystrica using NAVA involved a tiny premature girl, born in the 22[nd] week, who developed severe Bronchopulmonary Dysplasia (BPD). “She was in such poor condition that we couldn’t

Invitation to presentation of MilDef´s first quarter report 2024, on April 26

MilDef, a leading supplier of tactical IT, software solutions and services, will publish its first quarter report 2024 on April 26, at 08:00 am CET.A conference (on Teams) for investors, analysts and media will be held at 10.00-10.45 CET that same day. The report will be presented by Daniel Ljunggren, CEO and CFO Viveca Johnsson.  The presentation will be held in English and is concluded with a Q&A session, moderated by Olof Engvall, Head of Investor Relations. Presentation material will be made available on www.mildef.com the same morning. Notification is not required for

Invitation to the presentation of Ratos Interim report January-March 2024

The Interim report January-March 2024 will be released on Monday 29 April at 07.00 CEST.At 09.00 CEST will Jonas Wiström, President and CEO, and Jonas Ågrup, CFO, present the report.The presentation can be followed on Youtube via the following link; https://youtube.com/live/m1pxBSsaufo?feature=shareThe live presentation will be recorded and is available afterwards via the same link.Participants who wish to ask questions live are asked to pre-register, please send an e-mail to helena.jansson@ratos.com in advance for a personal invitation.The presentation and report will be available

Sandvik wins order in Mongolia for electric rotary drill rigs

Sandvik has received an order from Mongolyn Alt MAK LLC to supply electric rotary drill rigs for use at the Tsagaan Suvarga Project in Mongolia. The order is valued at approximately SEK 170 million and was booked in the first quarter 2024. The order includes five cable-electric DR410iE drills, with deliveries scheduled to begin in the second quarter 2024 and concluded by the fourth quarter of 2025. Tsagaan Suvarga ranks as the third-largest copper and molybdenum reserve in Mongolia. “We are very pleased to be selected to supply our advanced electric rotary drill rigs to Mongolyn Alt

Invitation to UPM’s webcast and conference call on Q1 2024 interim report

(UPM, Helsinki, 18 April 2024 at 10:00 EEST) – UPM will publish its Q1 2024 interim report on Thursday, 25 April 2024 at 09:30–10:00 EEST. After publishing, the report will be available on the company website at www.upm.com . A webcast and a conference call for analysts and investors begins at 13:15 EEST. The interim report will be presented in English by President and CEO Massimo Reynaudo and CFO Tapio Korpeinen. Participants can view the webcast online through this link . Those who wish to ask questions from

Correction (date) Presentation of Probi’s Q1 Report 2024

Probi’s report for the first quarter 2024 will be published on Tuesday, 23 April at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Anita Johansen and CFO Per Lindblad will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://ir.financialhearings.com/probi-q1-report-2024 

OrderYOYO A/S publishes Strong Q1 performance showing 33% ARR growth and EBITDA significantly higher than previous guidance showing 15% EBITDA margin. Guidance for 2024 raised

Company Announcement No. 72 - 2024 OrderYOYO A/SInside Information Copenhagen, April 18, 2024 Highlights Business continues to perform strongly and above guidance. Highly focused strategy solving digital challenges for our Restaurant Partners continues to reap rewards to the benefit of both our Restaurant Partners and OrderYOYO Q1 2024 results show a significant higher growth in ARR and Net Revenue than prior guidance. March 2024 ARR is thus DKK 300m corresponding to a growth of 33% compared to March 2023. Q1 2024 Net Revenue is DKK 73m corresponding to a growth of 35%

Diamyd Medical announces final outcome in the company’s rights issue

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW. On April 16, 2024, Diamyd Medical AB (publ) (“

There are no items matching the current filter
There are no more items matching the current filter
Back to top